Effect of compound α-ketoacid combined with calcium dobesilate in the treatment of renal interstitial fibrosis in patients with diabetic kidney disease
Objective To observe the effect of compound α-ketoacid combined with calcium oxybenzoate on renal interstital fibrosis in-dexes,serum high-sensitivity C-reactive protein(hs-CRP)and serum amyloid A(SAA)in patients with diabetic kidney disease(DKD).Methods 94 patients with DKD were selected and equally divided into 2 groups by random number table method.The con-trol group was treated with calcium dobesilate and the observation group was treated with compound α-ketoacid on the basis of the treatment of control group.The blood glucose indexes[2-hour postprandial plasma glucose(2 hPG)and fasting plasma glucose(FPG)],renal interstitial fibrosis indexes[hepatocyte growth factor(HGF),transforming growth factor β1(TGF-β1),vascular en-dothelial growth factor(VEGF)and homocysteine(Hcy)],hs-CRP and SAA levels,and renal function indexes[serum creatinine(Scr),urine albumin excretion rate(UAER),glomerular filtration rate(GFR)and blood urea nitrogen(BUN)]were detected be-fore and after treatment.The adverse reactions were recorded.Results After treatment,the levels of 2 hPG,FPG,TGF-β1,VEGF and Hcy in the observation group were significantly lower than those in the control group(P＜0.05),and the HGF level was signifi-cantly higher than that in the control group(P＜0.05).The serum hs-CRP and SAA levels,Scr,BUN and UAER in the observa-tion group were significantly lower than those in the control group(P＜0.05),and the GFR was significantly higher than that in the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P＞0.05).Conclusion Compound α-ketoacid combined with calcium dobesilate can better delay renal fibrosis,reduce serum hs-CRP and SAA levels,and improve renal function in patients with DKD,with high safety.
NETL
NSTL
万方数据
维普
